OCUL Long Call Strategy
OCUL (Ocular Therapeutix, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
OCUL (Ocular Therapeutix, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $2.02B, a beta of 0.93 versus the broader market, a 52-week range of 6.23-16.44, average daily share volume of 5.4M, a public-listing history dating back to 2014, approximately 274 full-time employees. These structural characteristics shape how OCUL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.93 places OCUL roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a long call on OCUL?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current OCUL snapshot
As of May 15, 2026, spot at $9.16, ATM IV 88.13%, IV rank 14.71%, expected move 25.27%. The long call on OCUL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this long call structure on OCUL specifically: OCUL IV at 88.13% is on the cheap side of its 1-year range, which favors premium-buying structures like a OCUL long call, with a market-implied 1-standard-deviation move of approximately 25.27% (roughly $2.31 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated OCUL expiries trade a higher absolute premium for lower per-day decay. Position sizing on OCUL should anchor to the underlying notional of $9.16 per share and to the trader's directional view on OCUL stock.
OCUL long call setup
The OCUL long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With OCUL near $9.16, the first option leg uses a $9.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed OCUL chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 OCUL shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $9.00 | $1.00 |
OCUL long call risk and reward
- Net Premium / Debit
- -$100.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$100.00
- Breakeven(s)
- $10.00
- Risk / Reward Ratio
- Unbounded
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
OCUL long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on OCUL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -99.9% | -$100.00 |
| $2.03 | -77.8% | -$100.00 |
| $4.06 | -55.7% | -$100.00 |
| $6.08 | -33.6% | -$100.00 |
| $8.11 | -11.5% | -$100.00 |
| $10.13 | +10.6% | +$13.11 |
| $12.16 | +32.7% | +$215.53 |
| $14.18 | +54.8% | +$417.95 |
| $16.20 | +76.9% | +$620.38 |
| $18.23 | +99.0% | +$822.80 |
When traders use long call on OCUL
Long calls on OCUL express a bullish thesis with defined risk; traders use them ahead of OCUL catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
OCUL thesis for this long call
The market-implied 1-standard-deviation range for OCUL extends from approximately $6.85 on the downside to $11.47 on the upside. A OCUL long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current OCUL IV rank near 14.71% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on OCUL at 88.13%. As a Healthcare name, OCUL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to OCUL-specific events.
OCUL long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. OCUL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move OCUL alongside the broader basket even when OCUL-specific fundamentals are unchanged. Long-premium structures like a long call on OCUL are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current OCUL chain quotes before placing a trade.
Frequently asked questions
- What is a long call on OCUL?
- A long call on OCUL is the long call strategy applied to OCUL (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With OCUL stock trading near $9.16, the strikes shown on this page are snapped to the nearest listed OCUL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are OCUL long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the OCUL long call priced from the end-of-day chain at a 30-day expiry (ATM IV 88.13%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$100.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a OCUL long call?
- The breakeven for the OCUL long call priced on this page is roughly $10.00 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current OCUL market-implied 1-standard-deviation expected move is approximately 25.27%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on OCUL?
- Long calls on OCUL express a bullish thesis with defined risk; traders use them ahead of OCUL catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current OCUL implied volatility affect this long call?
- OCUL ATM IV is at 88.13% with IV rank near 14.71%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.